Pádraig O'Sullivan (Cork North Central, Fianna Fail)
Link to this: Individually | In context | Oireachtas source

740. To ask the Minister for Health the number of medicines and the level of expenditure in 2022 on exempt medicinal products by the HSE; and if he will make a statement on the matter. [26091/23]

Stephen Donnelly (Wicklow, Fianna Fail)
Link to this: Individually | In context | Oireachtas source

As this is a service matter, I have asked the Health Service Executive to respond to the Deputy directly, as soon as possible.

Pádraig O'Sullivan (Cork North Central, Fianna Fail)
Link to this: Individually | In context | Oireachtas source

741. To ask the Minister for Health the number of patients who received medicines in 2022 under section 23 of the Health (Pricing and Supply of Medical Goods) Act 2013, which refers to supply of a medicine outside of the reimbursement list; whether or not any of these medicines had an orphan designation; and if he will make a statement on the matter. [26092/23]

Stephen Donnelly (Wicklow, Fianna Fail)
Link to this: Individually | In context | Oireachtas source

As this is a service matter, I have asked the Health Service Executive to respond to the Deputy directly, as soon as possible.

Pádraig O'Sullivan (Cork North Central, Fianna Fail)
Link to this: Individually | In context | Oireachtas source

742. To ask the Minister for Health if he will outline the bodies consulted in the review by an organisation (details supplied) of the reimbursement system; and if he will make a statement on the matter. [26093/23]

Stephen Donnelly (Wicklow, Fianna Fail)
Link to this: Individually | In context | Oireachtas source

In February, I published the Mazars Review which examined the governance arrangements around the HSE’s Drug Pricing and Reimbursement Process. As per their Report, the organisation undertook consultation with:

• The Health Service Executive
  • Primary Care Reimbursement Service
  • The Executive Management Team
  • The Drugs Group
• The National Centre for Pharmacoeconomics
• The Department of Public Expenditure and Reform
• The Rare Diseases Technology Review Committee
• The National Cancer Control Programme Technology Review Committee
• Patient representatives via the Rare Diseases Taskforce